Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 5
2003 2
2004 1
2005 3
2006 4
2007 4
2008 3
2009 3
2010 5
2011 14
2012 19
2013 13
2014 13
2015 10
2016 22
2017 14
2018 9
2019 12
2020 16
2021 11
2022 14
2023 11
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

185 results

Results by year

Filters applied: . Clear all
Page 1
Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study.
Choueiri TK, Eto M, Motzer R, De Giorgi U, Buchler T, Basappa NS, Méndez-Vidal MJ, Tjulandin S, Hoon Park S, Melichar B, Hutson T, Alemany C, McGregor B, Powles T, Grünwald V, Alekseev B, Rha SY, Kopyltsov E, Kapoor A, Alonso Gordoa T, Goh JC, Staehler M, Merchan JR, Xie R, Perini RF, Mody K, McKenzie J, Porta CG. Choueiri TK, et al. Among authors: hoon park s. Lancet Oncol. 2023 Mar;24(3):228-238. doi: 10.1016/S1470-2045(23)00049-9. Lancet Oncol. 2023. PMID: 36858721 Clinical Trial.
Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial.
Yu EY, Petrylak DP, O'Donnell PH, Lee JL, van der Heijden MS, Loriot Y, Stein MN, Necchi A, Kojima T, Harrison MR, Hoon Park S, Quinn DI, Heath EI, Rosenberg JE, Steinberg J, Liang SY, Trowbridge J, Campbell M, McGregor B, Balar AV. Yu EY, et al. Among authors: hoon park s. Lancet Oncol. 2021 Jun;22(6):872-882. doi: 10.1016/S1470-2045(21)00094-2. Epub 2021 May 12. Lancet Oncol. 2021. PMID: 33991512 Clinical Trial.
Central venous disease in hemodialysis patients.
Park HS, Choi J, Baik JH. Park HS, et al. Kidney Res Clin Pract. 2019 Sep 30;38(3):309-317. doi: 10.23876/j.krcp.19.025. Kidney Res Clin Pract. 2019. PMID: 31387161 Free PMC article. Review.
Blood Pressure Control in Patients with Diabetic Kidney Disease.
Kim Y, Kim W, Kim JK, Moon JY, Park S, Park CW, Park HS, Song SH, Yoo TH, Lee SY, Lee EY, Lee J, Jin K, Cha DR, Cha JJ, Han SY; Korean Diabetic Kidney Disease Working Group. Kim Y, et al. Among authors: park hs. Electrolyte Blood Press. 2022 Dec;20(2):39-48. doi: 10.5049/EBP.2022.20.2.39. Epub 2022 Dec 30. Electrolyte Blood Press. 2022. PMID: 36688208 Free PMC article. Review.
GARFIELD-AF: risk profiles, treatment patterns and 2-year outcomes in patients with atrial fibrillation in Germany, Austria and Switzerland (DACH) compared to 32 countries in other regions worldwide.
Haas S, Camm JA, Harald D, Steffel J, Virdone S, Pieper K, Brodmann M, Schellong S, Misselwitz F, Kayani G, Kakkar AK; GARFIELD-AF Investigators. Haas S, et al. Clin Res Cardiol. 2023 Jun;112(6):759-771. doi: 10.1007/s00392-022-02079-y. Epub 2022 Sep 12. Clin Res Cardiol. 2023. PMID: 36094573
Recent developments in biorefining of macroalgae metabolites and their industrial applications - A circular economy approach.
Ashokkumar V, Jayashree S, Kumar G, Aruna Sharmili S, Gopal M, Dharmaraj S, Chen WH, Kothari R, Manasa I, Hoon Park J, Shruthi S, Ngamcharussrivichai C. Ashokkumar V, et al. Among authors: hoon park j. Bioresour Technol. 2022 Sep;359:127235. doi: 10.1016/j.biortech.2022.127235. Epub 2022 Apr 26. Bioresour Technol. 2022. PMID: 35487449 Review.
185 results